Exit & Commercialization Strategies: Maximizing Your Investments

The exit strategies of life sciences companies have become more varied due to the current situation being experienced by global capital markets. This is primarily the case for German life sciences companies as well. The choice of exit scenario must be made carefully based on the individual circumstances of the company. The panelists will present and discuss the different exit variations and commercialization strategies, specifically when considering exits of German life sciences companies in other countries (such as the United States or Switzerland)

• Collaboration Deals
• Joint Ventures
• Staged Exits
• Milestone Agreements
• Indemnification vs. Warranties
• Sub-licensing structures
• Big pharma deal terms

Speakers:

• Sven Riethmueller (Attorney, member of New York and Massachusetts Bars), Foley & Lardner LLP
• Dr. Irina Staatz-Granzer, Staatz Business Development and Strategy
• Professor Dr. Christof Hettich (Rechtsanwalt), Rittershaus